What are the etiology, pathophysiology, diagnostic work‑up, and management strategies for female pattern hair loss?

Female Pattern Hair Loss: Comprehensive Overview

Introduction

Female pattern hair loss (FPHL) is a non-scarring, progressive hair thinning disorder characterized by follicular miniaturization, primarily affecting the frontal, central, and parietal scalp while typically sparing the frontal hairline. 1, 2 This represents the most common cause of alopecia in women, with prevalence increasing significantly with age and carrying substantial psychological morbidity that impacts quality of life 3, 4.

---

Etiology

Genetic Factors

• Multifactorial genetic predisposition involving polymorphisms in androgen and estrogen receptor genes plays a central role in disease susceptibility 4, 5
• High-throughput genetic analyses have revealed molecular mechanisms underlying disease susceptibility, though specific inheritance patterns remain complex 5

Hormonal Influences

• The role of androgens, particularly dihydrotestosterone (DHT), remains unclear in FPHL compared to male androgenetic alopecia 6
• Many affected women lack clinical or biochemical markers of hyperandrogenism, suggesting significant androgen-independent mechanisms 4
• Free androgen index (FAI) appears to be a better biomarker for predicting hyperandrogenism than testosterone or SHBG alone in women with FPHL 7

Additional Contributing Factors

• Environmental factors contribute to disease onset, though specific triggers remain poorly defined 2
• Inflammation may play a role in the pathophysiologic process 2

---

Pathophysiology

The core pathologic process involves progressive follicular miniaturization with shortened anagen phases and lengthened telogen phases 6. This results in:

• Gradual transformation of terminal hairs into vellus-like miniaturized follicles 8
• Decreased hair density over affected areas without complete follicular destruction 2
• Preservation of hair follicles, maintaining potential for regrowth with appropriate intervention 3

The exact mechanisms driving miniaturization remain incompletely understood and appear multifactorial, involving both androgen-dependent and androgen-independent pathways 4, 8.

---

Diagnosis

Clinical Presentation

FPHL manifests as slowly progressive hair thinning mainly over the vertex and upper parietal scalp, with frontal hairline typically preserved 2. Key clinical features include:

• Diffuse reduction in hair density over crown and frontal scalp 4
• Less severe miniaturization compared to male pattern baldness 2
• Retention of frontal hairline (distinguishing feature) 4

Diagnostic Evaluation

Most cases can be diagnosed through medical history and physical examination alone, without requiring invasive testing 3. The diagnostic workup should include:

Essential Components:

• Thorough history: onset, progression pattern, family history, menstrual irregularities, signs of hyperandrogenism (hirsutism, acne), medications, nutritional status 2, 4
• Clinical examination: hair density assessment, pattern distribution, scalp condition 2
• Hair loss evaluation tests: hair pull test, hair count 2
• Dermoscopy: reveals hair diameter diversity, peripilar signs, and follicular patterns characteristic of miniaturization 2

When to Perform Additional Testing:

• Scalp biopsy: diagnostic but usually not required; reserve for atypical presentations or diagnostic uncertainty 3
• Biochemical assessment: indicated only in women with clinical signs of hyperandrogenism (hirsutism, acne, menstrual irregularities) 4
  • Measure: total testosterone, FAI (calculated from testosterone and SHBG), DHEA-S 7
  • FAI is recommended as the preferred biomarker over isolated testosterone or SHBG measurements 7
• Imaging studies: perform in patients with biochemical hyperandrogenism to evaluate for ovarian or adrenal disorders 3, 4

Screening Recommendations:

• Screen patients for metabolic syndrome and cardiovascular risk factors, as FPHL may serve as a marker for increased cardiovascular and metabolic disease risk 1, 4

Differential Diagnosis

Chronic telogen effluvium remains the most important differential diagnosis 4. Other considerations include:

• Telogen effluvium (acute) 9
• Diffuse alopecia areata 9
• Trichotillomania 9
• Early scarring alopecia 9
• Systemic lupus erythematosus 9

---

Management

Treatment Principles

Early initiation of treatment is critical because available therapies are more effective at arresting progression than stimulating regrowth 3, 4. The progressive nature of FPHL mandates long-term treatment for sustained effect 4.

First-Line Medical Therapy

Topical minoxidil remains the first-line treatment with the highest level of evidence and is the only FDA-approved medication for FPHL 6, 10. Key points:

• Effectively arrests hair loss progression in most patients with mild-to-moderate FPHL 3
• Should be initiated early for optimal results 4
• Approximately 40% of patients do not show improvement, necessitating alternative approaches 10

Second-Line Medical Therapy

Oral antiandrogens (spironolactone and cyproterone acetate) form the second-line treatment for mild-to-moderate FPHL 3, 4. Consider when:

• Patient shows inadequate response to topical minoxidil 3
• Clinical or biochemical evidence of hyperandrogenism exists 4
• Patient requires contraception (can combine with oral contraceptives) 6
• Genetic polymorphisms in androgen receptors may predict treatment response to antiandrogens 4

Topical antiandrogens may be used in combination with topical minoxidil or as alternatives to oral medications, likely with fewer systemic adverse effects 6.

Combination Therapy

Combinations of treatments tend to be more efficacious than monotherapy 8. Effective combinations include:

• Topical minoxidil plus oral antiandrogens 3
• Medical therapy plus nutritional supplements 8
• Medical therapy plus low-level laser therapy 1, 8

Emerging and Adjunctive Therapies

New treatment modalities showing promise include:

• Microneedling 1
• Low-level laser therapy 1, 8
• Autologous fat transfer 1

Non-Medical Management

Cosmetic camouflage should be offered to patients desiring greater hair density, particularly those with inadequate response to medical therapy 4, 10. Options include:

• Hair systems 3
• Cosmetic concealment products 4

Surgical hair transplantation may be considered for carefully selected patients with severe FPHL who have failed medical management 3, 4. Patient selection is critical for successful outcomes.

Treatment Algorithm

1. Mild-to-moderate FPHL without hyperandrogenism: Start topical minoxidil 10
2. Inadequate response to minoxidil or signs of hyperandrogenism: Add oral antiandrogens (after appropriate biochemical evaluation and contraception counseling) 3, 4
3. Consider combination therapy early for enhanced efficacy 8
4. Supplement with cosmetic camouflage as needed for patient satisfaction 4
5. Reserve surgery for severe cases unresponsive to medical management 3

Important Caveats

• All treatments work best when initiated early in the disease course 8
• Medical treatments arrest progression and reverse miniaturization in most patients with mild-to-moderate FPHL when used correctly 3
• Long-term adherence is essential; discontinuation typically results in recurrence of hair loss 4
• Oral antiandrogens require contraception counseling due to teratogenic potential 6
• Nutritional supplements have an adjuvant role but should not replace evidence-based medical therapy 8